BOSTON (Reuters) - The
drug-mixing company at the heart of a deadly U.S. meningitis outbreak solicited bulk orders
from physicians and failed to require proof of individual patient prescriptions as
required under state regulations, emails to a customer show.
Reuters reviewed more than a dozen emails
that show the New England Compounding Center, contrary to Massachusetts
regulations, sold drugs without requiring physicians to supply individual
patient prescriptions.
The customer confirmed that NECC supplied the
clinic with drugs without patient names or prescriptions.
NECC, based in Framingham, Massachusetts, distributed thousands of vials of a
contaminated steroid that has put 14,000 people at risk of contracting
meningitis and killed 14 people.
The emails support assertions made this
week by state pharmacy regulators that the compounding firm, which was
authorized to deliver products only in response to patient-specific
prescriptions, had violated its license in Massachusetts.
The emails also indicate that NECC referred
business to a sister company, Ameridose LLC, despite a statement by Ameridose earlier this
week that the two operated separately.
To read full story click here
No comments:
Post a Comment